CHRS Live signaler | Maksimer profitt med Getagraph.com

KJøP 115609 min ago

@ $2.65

Utstedt: 14 feb 2024 @ 19:49

Avkastning: -14.34%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: 0.62 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	1.52M
Gjennomsnittsvolum	2.44M
Markedsverdi	257.64M
EPS	$0 ( 2024-03-13 )
Neste inntjeningsdato	( $-0.0500 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.900
ATR14	$0.00500 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-20	Erbez Georgia	Buy	54 000	Stock Option (Right to Buy)
2024-02-20	Erbez Georgia	Buy	0
2024-02-09	Wahlstrom Mats	Buy	99 988	Common Stock
2024-02-09	Wahlstrom Mats	Sell	99 988	Common Stock
2024-02-01	Wahlstrom Mats	Buy	44 991	Common Stock

INSIDER POWER
42.64
Last 94 transactions
Buy: 4 570 164 \| Sell: 1 886 237

Volum Korrelasjon

Lang: 0.23 (neutral)

Kort: -0.73 (moderate negative)

Signal:(48.908) Neutral

Coherus BioSciences Inc Korrelasjon

10 Mest positive korrelasjoner
STRA	0.91
AVID	0.906
KPTI	0.887
EGRX	0.884
PARA	0.883
PINC	0.877
COLM	0.873
MDWD	0.868
IVAC	0.866
KTCC	0.865

10 Mest negative korrelasjoner
MORF	-0.905
RXDX	-0.901
WPRT	-0.891
IMGN	-0.882
RESN	-0.875
MDWT	-0.872
FLMN	-0.871
ACOR	-0.866
ACVA	-0.861
IDCC	-0.857

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Coherus BioSciences Inc Korrelasjon - Valuta/Råvare

-0.18
( neutral )

-0.26
( neutral )

0.00
( neutral )

-0.46
( neutral )

0.17
( neutral )

Coherus BioSciences Inc Økonomi

Annual	2023
Omsetning:	$257.24M
Bruttogevinst:	$94.46M (36.72 %)
EPS:	$-2.53

FY	2023
Omsetning:	$257.24M
Bruttogevinst:	$94.46M (36.72 %)
EPS:	$-2.53

FY	2022
Omsetning:	$211.04M
Bruttogevinst:	$140.96M (66.79 %)
EPS:	$-4.21

FY	2021
Omsetning:	$326.55M
Bruttogevinst:	$268.96M (82.36 %)
EPS:	$-3.63

Financial Reports:

No articles found.

Coherus BioSciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Sanntidsoppdatering for Coherus BioSciences Inc [CHRS]

Upcoming Earnings Alert